Search Results 1831-1840 of 16962 for ozempic

  1. Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis - Mayo Clinic

    The primary hypothesis of the study is that treatment with pacritinib results in a greater proportion of patients achieving ≥ 35% reduction in spleen volume ...

  2. REpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study (ICH03) - Mayo Clinic

    About this study. The purpose of this study is to determine if surgical clot reduction after ICH reduces the risk of progressive cognitive decline.

  3. Head and neck cancers - Doctors and departments - Mayo Clinic

    Learn about innovative treatment for throat cancers, mouth cancers, tongue cancers, tonsil cancers and other cancers that affect the head and neck.

  4. DNA Methylation in Adenocarcinoma of the Prostate: Tissue Validation of Biomarkers and Pilot Testing in Blood - Mayo Clinic

    About this study. The study will be performed in two phases: Phase I will be performed for biologic validation of marker candidates from a discovery cohort ...

  5. Identification of risk factors and risk markers in Patients with Cavernous Malformations - Mayo Clinic

    This study aums to determine whether various markers of vascular stability are predictive of clinical events (intracerebral hemorrhage or focal neurologic ...

  6. Breast cancer - Doctors and departments - Mayo Clinic

    Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.

  7. Breast cancer - Doctors and departments - Mayo Clinic

    Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.

  8. Loncastuximab Tesirine in WM - Mayo Clinic

    About this study. The purpose of this study is to examine the safety and effectiveness of loncastuximab tesirine as a possible treatment for participants ...

  9. Breast cancer - Doctors and departments - Mayo Clinic

    Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.

  10. Phase 1/2a Clinical Trial Of PR001 (LY3884961) In Patients With Parkinson's Disease With At Least One GBA1 Mutation (PROPEL)

    The purpose of this study is to evaluate the safety of intracisternal LY3884961 administration in patients with moderate to severe Parkinson's disease with at ...